DMP 811

Drug Profile

DMP 811

Alternative Names: DUP 811; L 708404

Latest Information Update: 04 Dec 1995

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihypertensives; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 04 Dec 1995 A study in animals has been added to the pharmacokinetics section
  • 01 Jun 1995 Discontinued-Preclinical for Hypertension in USA (PO)
  • 01 Jun 1995 Discontinued-Preclinical for Hypertension in Afghanistan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top